Referred to the House Committee on Energy and Commerce.
This resolution is a nonbinding statement from the House of Representatives supporting the designation of April 5, 2026 as Barth Syndrome Awareness Day. It highlights the medical challenges of Barth syndrome and urges improved awareness, earlier diagnosis, and more research and treatment development. It does not create new law, appropriate funds, or require executive-branch action.
This is a simple House resolution considered only in the House of Representatives; it does not go to the Senate or the President and does not have the force of law.
This House resolution expresses support for designating April 5, 2026, as Barth Syndrome Awareness Day.
It explains Barth syndrome’s clinical features, prevalence, and challenges, notes the need for research and diagnostics, and recognizes relevant actors like the Barth Syndrome Foundation and Kennedy Krieger Institute.
The resolution also highlights the role of the Orphan Drug Act and FDA patient-focused programs and encourages attention to regulatory pathways for ultrarare disease drug development.
Text is a nonbinding House resolution that does not create law; adoption by the House likely, but it cannot become law as written.
Relative to its intended legislative type, this bill functions as a conventional commemorative resolution: it provides a substantive factual preamble and then issues declarative support for designating April 5, 2026 as Barth Syndrome Awareness Day while listing awareness and research priorities. The level of operational, fiscal, and legal detail is minimal but appropriate for a symbolic designation.
Left emphasizes need for funding and access commitments
These are examples from the analysis, not a ranked list of the most-affected groups.
Left emphasizes need for funding and access commitments
Likely welcomes the resolution as a compassionate, patient-centered recognition of a rare disease and a prompt to accelerate research.
Would emphasize the need for federal support, equitable access to care, and incorporating patient perspectives into drug development.
Likely supportive of the nonbinding, awareness-focused resolution while wanting clear limits on fiscal or regulatory commitments.
Views it as a reasonable, low-cost way to spotlight unmet medical needs, but seeks practical follow-up steps.
Generally supportive of an awareness day for a rare, life-threatening disease but cautious about language implying regulatory or budgetary change.
Prefers symbolic recognition without new federal obligations or expanded bureaucratic programs.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Text is a nonbinding House resolution that does not create law; adoption by the House likely, but it cannot become law as written.
The bill has not accumulated any surfaced votes yet.
Left emphasizes need for funding and access commitments
Text is a nonbinding House resolution that does not create law; adoption by the House likely, but it cannot become law as written.
Relative to its intended legislative type, this bill functions as a conventional commemorative resolution: it provides a substantive factual preamble and then issues declarative support for designating April 5, 2026 as…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.